Periprosthetic joint infection (PJI) is a devastating complication for the patient and the health care providers. Its incidence is between 1% and 3% in primary and 4% and 6% in revision total joint arthroplasties. The diagnosis can be straightforward with purulent discharge from the joint but may also be confusing especially when associated with medical morbidities. Often, infection leads to multiple operations, prolonged use of antibiotics, extensive utilization of medical resources, and substantial social, economic, or even psychological impacts on the patients, family, hospitals, physicians, and payers. It is estimated that the direct medical cost for treating a PJI is 3 times to the medical cost without infection in revisions and 10 times to the medical cost with uneventful primary cases. As the demand for total joint arthroplasties and the burden of PJI increase globally, knowledge and technologies for detecting, preventing, and managing PJI need to be shared to provide better care to patients.
In this special issue, we included studies of economic analysis on the treatment of PJI (D. This special issue cannot cover all the issues dealing with PJI. However, by increasing the clinicians and surgeons awareness about PJI, the burdens and challenges could be met by putting more efforts to prevent infection, to design novel bacteria-resistant implants, to improve diagnostic sensitivity and accuracy, to make better antibiotic-loaded spacers, and to develop strategies in treating drug-resistant strains or fungal infections. These works need the collaboration between academic researchers and clinicians to translate basic science to clinical practice.
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